←Back to Expert Scholars
Translational Medicine / 转化医学ADC Payload Innovation
Andrew Bhatt
PhD
🏢AbbVie🌐USA
Director, ADC Development
35
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Andrew Bhatt has contributed to the development of calicheamicin-based ADCs including gemtuzumab ozogamicin and inotuzumab ozogamicin. His work on ADC clinical pharmacology has informed dosing strategies and toxicity management across ADC programs. He continues to advance next-generation DNA-damaging payloads with improved therapeutic windows.
Share:
🧪Research Fields 研究领域
Calicheamicin payloads
DNA-damaging ADC
Inotuzumab ozogamicin
Gemtuzumab ozogamicin
ADC clinical pharmacology
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Andrew Bhatt 的研究动态
Follow Andrew Bhatt's research updates
留下邮箱，当我们发布与 Andrew Bhatt（AbbVie）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment